Trial Profile
A Phase II/III Study of Dalotuzumab (MK-0646) Treatment in Combination With Cetuximab and Irinotecan for Patients With Metastatic Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Dalotuzumab (Primary) ; Cetuximab; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 15 Jun 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 01 Sep 2015 Primary endpoint (Overall survival) has not been met according to the results published in the Journal of the National Cancer Institute.
- 01 Sep 2015 Primary endpoint (Progression-free survival) has not been met according to the results published in the Journal of the National Cancer Institute.